Literature DB >> 20567941

Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.

Famke L Schneiders1, H Pieter van den Berg, Godefridus J Peters, Henk M W Verheul, Hans J van der Vliet.   

Abstract

Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 58 year old woman with metastatic rectal carcinoma who developed severe gastrointestinal toxicity when the thus far well-tolerated intravenous 5-fluorouracil (5-FU)/leucovorin containing chemotherapeutic regimen was replaced by the same chemotherapeutic regimen in combination with the oral 5-FU prodrug capecitabine. This increased toxicity is probably due to the intracellular retention of polyglutamated folates induced by prior leucovorin therapy which, upon subsequent administration of capecitabine, will result in an enhanced and prolonged inhibition of the, for DNA synthesis important, enzyme thymidylate synthase, essentially creating a situation equivalent to overdosing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567941     DOI: 10.1007/s12032-010-9598-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  11 in total

1.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

Review 2.  [Chemotherapy of patients with colorectal carcinoma].

Authors:  C J A Punt
Journal:  Ned Tijdschr Geneeskd       Date:  2005-06-25

3.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

Review 4.  Capecitabine: a review.

Authors:  Christine M Walko; Celeste Lindley
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

5.  Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.

Authors:  Christopher Poole; Jill Gardiner; Chris Twelves; Patrick Johnston; Peter Harper; Jim Cassidy; Jayne Monkhouse; Ludger Banken; Erhard Weidekamm; Bruno Reigner
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-10       Impact factor: 3.333

6.  A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.

Authors:  J Cassidy; L Dirix; D Bissett; B Reigner; T Griffin; D Allman; B Osterwalder; A T Van Oosterom
Journal:  Clin Cancer Res       Date:  1998-11       Impact factor: 12.531

7.  Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines.

Authors:  D M Boarman; C J Allegra
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

8.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

Authors:  Ivo M Hennig; Jay D Naik; Sarah Brown; Alex Szubert; David A Anthoney; David P Jackson; Alan M Melcher; S Michael Crawford; Christopher Bradley; Julia M B Brown; Matthew T Seymour
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

View more
  2 in total

Review 1.  Colon Cancer Pharmacogenetics: A Narrative Review.

Authors:  Álvaro Esteban Alfaro Alfaro; Brayan Murillo Castillo; Eugenia Cordero García; Javier Tascón; Ana I Morales
Journal:  Pharmacy (Basel)       Date:  2022-08-05

2.  Effect of onion flavonoids on colorectal cancer with hyperlipidemia: an in vivo study.

Authors:  Yongshan He; Heiying Jin; Wei Gong; Chunxia Zhang; Acheng Zhou
Journal:  Onco Targets Ther       Date:  2014-01-08       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.